We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Learn about the common and serious side effects of Exondys 51 (eteplirsen), a medication for Duchenne muscular dystrophy. This guide covers symptoms, management strategies, kidney risks, infusion reactions, and when to seek medical help to ensure safe treatment.

Sleeping tablets can help manage insomnia and sleep disorders when used correctly. This guide explains types, benefits, risks, and safe usage tips for better sleep health.
April 11, 2026
Explore the short-term and long-term effects of Adderall on the brain, including its uses, side effects, risks of misuse, and the importance of medical supervision for safe and effective treatment.
April 1, 2026

Exondys 51 (eteplirsen) is a medication that offers a ray of hope for individuals living with Duchenne muscular dystrophy (DMD). Approved by the U.S. Food and Drug Administration (FDA) in 2016, it targets a specific genetic mutation in patients amenable to exon 51 skipping. While Exondys 51 can be a crucial part of a treatment regimen, like all medications, it comes with potential side effects. Understanding these effects is vital for patients, caregivers, and healthcare providers to ensure safe and effective use.
This comprehensive guide aims to shed light on the common and serious side effects associated with Exondys 51, how to recognize them, and when to seek medical attention. Our goal is to empower you with the knowledge needed to navigate treatment with confidence and proactively manage any adverse reactions.
Exondys 51 is an antisense oligonucleotide designed to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. DMD is a severe, progressive muscle-wasting disease caused by a mutation in the gene that codes for dystrophin, a protein essential for muscle cell integrity. Without functional dystrophin, muscle fibers become damaged and are eventually replaced by fibrous and fatty tissue, leading to progressive muscle weakness.
Eteplirsen works by binding to exon 51 of the dystrophin pre-mRNA, allowing for its exclusion during mRNA processing. This process, known as 'exon skipping,' aims to produce a truncated but partially functional dystrophin protein. While not a cure, this approach seeks to slow the progression of muscle degeneration, potentially improving motor function and quality of life for eligible patients.
Exondys 51 is administered as an intravenous (IV) infusion, typically once weekly, under the supervision of a healthcare professional.
Side effects are unintended and often undesirable effects of a drug. They can range from mild and temporary to severe and life-threatening. The occurrence and severity of side effects can vary greatly among individuals, depending on factors such as dosage, individual sensitivity, overall health, and concurrent medications.
It's important to remember that the decision to use Exondys 51 involves weighing the potential benefits against the potential risks. Your healthcare team will discuss these with you in detail. Open communication with your doctor about any symptoms or concerns you experience during treatment is crucial.
Clinical trials for Exondys 51 have provided data on the frequency of various side effects. It's common for patients to experience at least some mild side effects. Serious side effects are less common but require immediate attention.
Many patients receiving Exondys 51 may experience one or more of these common side effects. These are generally mild to moderate in severity and may improve over time as your body adjusts to the medication. However, if any of these become bothersome or persistent, you should inform your doctor.
It is essential to report any new or worsening symptoms to your healthcare provider, even if they seem minor.
While less frequent, certain side effects of Exondys 51 can be serious and require immediate medical attention. Being aware of these and knowing the signs to look for can be life-saving.
One of the most significant serious side effects associated with Exondys 51 is the potential for kidney problems, specifically renal toxicity. This is believed to be due to the accumulation of the drug in the renal tubules.
Infusion-related reactions can occur during or shortly after the administration of Exondys 51. These reactions can range from mild to severe and may include:
If you experience any signs of a severe infusion reaction, especially difficulty breathing or swelling, seek emergency medical help immediately. Your healthcare team is trained to recognize and manage these reactions and may administer medications (like antihistamines or corticosteroids) before or during the infusion to help prevent them.
Beyond acute infusion reactions, some patients may experience delayed hypersensitivity reactions. These can manifest as skin rashes, itching, or other allergic symptoms that appear hours or even days after an infusion. Always inform your doctor about any unusual symptoms, even if they appear delayed.
It can sometimes be difficult to distinguish between a minor symptom and a sign of a serious problem. When in doubt, it's always best to err on the side of caution and contact your healthcare provider. Here are clear guidelines:
Managing side effects effectively is a collaborative effort between you, your caregivers, and your healthcare team. Here are some strategies:
The diagnosis of side effects primarily relies on:
While not all side effects can be prevented, several strategies are employed to minimize risks:
Here are answers to some frequently asked questions regarding Exondys 51 and its side effects:
A: Exondys 51 has been approved by the FDA, indicating that its benefits are considered to outweigh its known risks for the specific patient population it targets. However, like all medications, it has potential side effects, some of which can be serious. Your doctor will discuss the safety profile and help you weigh the risks and benefits in your individual case.
A: The duration of side effects can vary. Common side effects like infusion site reactions or mild fatigue might be temporary and resolve within hours to days. More persistent issues, like joint pain, might last longer. Serious side effects, such as kidney problems, require ongoing management and monitoring by your healthcare team.
A: Renal toxicity is a known serious side effect. While regular monitoring aims to detect and manage kidney issues early, there is a potential for long-term damage if not properly addressed. It is crucial to adhere to all recommended kidney function tests.
A: If you miss an infusion, contact your healthcare provider immediately. They will advise you on the best course of action, which typically involves rescheduling the missed dose as soon as possible. Do not wait until your next scheduled infusion without speaking to your doctor.
A: Generally, there are no specific dietary restrictions directly imposed by Exondys 51. However, if you experience gastrointestinal side effects like vomiting, your doctor or a dietitian might suggest dietary adjustments to help manage these symptoms. Always discuss any dietary concerns with your healthcare team.
Exondys 51 represents a significant therapeutic option for eligible individuals with Duchenne muscular dystrophy. While its potential to alter the course of this devastating disease offers great hope, it's paramount to approach treatment with a thorough understanding of its associated side effects.
By being well-informed about common and serious adverse reactions, actively communicating with your healthcare team, and adhering to monitoring guidelines, you can play a crucial role in ensuring the safest possible treatment experience. Always remember that your medical team is your primary resource for personalized advice and management of your condition and its treatment.
Curious if Pepto-Bismol can help your stomach after drinking? We explore the potential risks and what the research says about mixing Pepto-Bismol and alcohol, plus safer alternatives for hangover relief.
April 1, 2026